Ipsen To Set Up Its Own U.S. Oncology Team For Somatuline® Depot&#0174 (Lanreotide) Injection In Neuroendocrine Tumors

Published: Jan 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News:

Ipsen (Euronext : IPN ; ADR : IPSEY) today announced its decision to set up its own oncology team to commercialize Somatuline® Depot® (lanreotide) 120 mg Injection (referred to as Somatuline®) in neuroendocrine tumors (NETs) in the US.

Help employers find you! Check out all the jobs and post your resume.

Back to news